Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus cisplatin versus olaparib in mCRPC with DNA repair gene defects
ChiCTR2000036694Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of olaparib and cisplatin in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Radiologic progression and Time to PSA progression. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
olaparibcisplatin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2000036694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036694.